OTHER · Unmapped registry intervention
CT imaging, functional PET imaging
Find medicine records ·
Find other trials using this name
Clinical trial
FDG Uptake and Lung Blood Flow in PAH Before and After Treatment With Ambrisentan
NCT02958358
Drugs and interventions used in this trial
1 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
No matching interventions in this trial.
Study at a glance
Registry-backedFDG Uptake and Lung Blood Flow in PAH Before and After Treatment With Ambrisentan
Design: INTERVENTIONAL · Status: WITHDRAWN · Phase: NA
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Interventions
Sponsors & collaborators
Robert Scott Harris, M.D.lead sponsor
Gilead Sciencescollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT02958358 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.